These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1356 related items for PubMed ID: 23768755

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM, Wozniak A.
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [Abstract] [Full Text] [Related]

  • 4. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
    Rossi A, Pasquale R, Esposito C, Normanno N.
    Cancer Treat Rev; 2013 Aug; 39(5):489-97. PubMed ID: 23022519
    [Abstract] [Full Text] [Related]

  • 5. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ.
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [Abstract] [Full Text] [Related]

  • 6. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Liao BC, Lin CC, Yang JC.
    Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
    [Abstract] [Full Text] [Related]

  • 7. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
    Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ.
    Cancer; 2011 Jan 01; 117(1):143-51. PubMed ID: 20803614
    [Abstract] [Full Text] [Related]

  • 8. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F.
    J Cell Physiol; 2005 Dec 01; 205(3):355-63. PubMed ID: 15895392
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.
    Imai H, Shukuya T, Takahashi T, Fujiwara S, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Harada H, Endo M, Nakajima T, Yamamoto N.
    Anticancer Res; 2013 Aug 01; 33(8):3279-84. PubMed ID: 23898092
    [Abstract] [Full Text] [Related]

  • 10. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH, Soo RA.
    Drug Des Devel Ther; 2015 Aug 01; 9():5641-53. PubMed ID: 26508839
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 12. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
    Peters S, Zimmermann S, Adjei AA.
    Cancer Treat Rev; 2014 Sep 01; 40(8):917-26. PubMed ID: 25027951
    [Abstract] [Full Text] [Related]

  • 13. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
    Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K, O'Byrne K.
    J Clin Pathol; 2012 Jan 01; 65(1):1-7. PubMed ID: 22039281
    [Abstract] [Full Text] [Related]

  • 14. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD, Buckingham L, Coon J.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [Abstract] [Full Text] [Related]

  • 15. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q, Yang XN, An SJ, Zhang XC, Yang JJ, Zhong WZ, Liao RQ, Chen ZH, Su J, Xie Z, Wu YL.
    Eur J Cancer; 2011 Sep 01; 47(13):1962-70. PubMed ID: 21616658
    [Abstract] [Full Text] [Related]

  • 16. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T, Liu G, Tsao MS.
    Oncogene; 2009 Aug 01; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
    Cho SH, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.
    Cancer Chemother Pharmacol; 2012 Aug 01; 70(2):315-20. PubMed ID: 22760226
    [Abstract] [Full Text] [Related]

  • 18. EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC.
    Gorden KJ, Mesbah P, Kolesar JM.
    J Oncol Pharm Pract; 2012 Jun 01; 18(2):245-9. PubMed ID: 21733906
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications.
    Ovcaricek T, Cufer T, Kern I, Sodja E, Sadikov A.
    J Cancer Res Ther; 2013 Jun 01; 9(2):261-6. PubMed ID: 23771370
    [Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ.
    Lung Cancer; 2009 Jul 01; 65(1):80-4. PubMed ID: 19059670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.